Search This Blog

Friday, November 6, 2020

HHS Proposes Review of All Its Existing Regulations

Can regulations just disappear? It might happen under a proposed rule announced Wednesday by the Department of Health and Human Services (HHS).

"This is the biggest regulatory reform effort in the biggest regulatory agency," Brian Harrison, HHS chief of staff, said Wednesday on a phone call with reporters. "We're proposing a rule that will require regular review of regulations to ensure that they're up to date and delivering the promised benefits."

Under the proposal, the department will review each of its regulations -- with some exceptions -- every 10 years. Those regulations that are currently more than 10 years old must be reviewed within 2 years of the enactment of the proposed rule; regulations that aren't reviewed during that time will expire, Harrison said.

In other words, any older rules that HHS fails to review during the 2-year window would simply vanish from the Code of Federal Regulations.

Exceptions to the review requirement include regulations that are jointly issued with other agencies, those that legally cannot be rescinded, and those issued with respect to a military or foreign affairs function or addressed solely to internal management or personnel matters.

A 30-day comment period began Wednesday for most of the rule, though a few parts have 60-day periods.

Decades' Worth of Regulations

During the question-and-answer session of the media call, one reporter noted that HHS was founded in 1953. "If this is all the regulations put out by HHS -- that's 67 years' worth of regulations -- if this moves forward the clock starts ticking and you have 2 years to review 67 years' worth of regulations, and if you don't get through them they automatically go away?" she asked. (Actually, it would only affect the last 57 years of regulations, since it doesn't apply to regulations less than 10 years old.)

"That's generally correct, although there are certain exceptions -- but yeah, basically 10 years from promulgation of the [affected] rule or 2 years from promulgation of this [new] rule, whichever is longer," Harrison replied.

Another reporter asked about whether HHS has the authority to sunset regulations wholesale. "We have the existing rulemaking authority as a legal basis for this proposal," he said. Speaking on background, another HHS official added that "this is using existing statutory authorities for our regulations, and the proposal is simply to amend our regulations to add expiration dates if a condition were not to be met. That's a fairly common practice in the government, so we're pretty confident of the legal basis for this."

Little Effect on Outpatient Practices

The rule is not likely to have too much effect on most outpatient physicians' day-to-day practices, said Eric Knickrehm, a healthcare attorney at Ballard Spahr, a law firm here. That's because many of the rules that affect physicians are implementing laws -- such as the Stark self-referral law or Anti-Kickback Statute -- that themselves don't have expiration dates, so the implementing regulations don't expire.


Other regulations affecting doctors, such as the Medicare Physician Fee Schedule annual rule, "would fall outside of this requirement because they're already being reviewed or appended on an annual basis," he said in a phone interview.

Mark Polston, former chief litigation counsel at the Centers for Medicare & Medicaid Services (CMS) and a partner in the healthcare law practice at King & Spalding here, noted that the rule is quite broad. It would include rules on "food safety, drug approval, and healthcare financing," he said.

"I don't think they're saying they would have drug approvals expire if drugs are approved ... but I think what they're saying is that if there is a rule out there that describes what a manufacturer of a drug must do to get FDA approval," that might fall under the review requirement. So you could conceivably have rules about how drugs and devices are approved -- all be subject to this proposed rule, he said.

Some of the healthcare financing rules that might fall under the review requirement could "conceivably be disruptive" to hospitals, Polston said. For example, "hospitals that operate nursing programs or other programs where they educate and train allied health professionals, Medicare by statute is required to pay for costs associated with some of those programs, and there's a regulation by which the secretary implemented that. That regulation has a substantial economic impact on small entities" -- which is required for the rule to be subject to review -- "because small hospitals sometimes have these programs ... Would that rule merely go away if the secretary didn't review its economics impact and if so, what about the income stream for those hospitals that are paid for those services?"

Gail Wilensky, PhD, senior fellow at Project HOPE, said the idea of reviewing old regulations "is certainly a sensible idea, to see whether or not they remain relevant in their current form."

But "whether you can get rid of regulations would depend on whether or not the implementing legislation has changed," said Wilensky, who served as CMS administrator under President George H.W. Bush.

"You can't get rid of regulations willy-nilly if the legislation driving them is still around" without following the Administrative Procedures Act, which requires HHS to issue a Notice of Proposed Rulemaking, allow time for the public to comment on the proposed rule, and address the comments when the final rule is written, she said.

And, Wilensky added, HHS will be reviewing all of these regulations at the same time it is writing regulations for new legislation that's being passed. "It's not like [they can say] 'We won't have any more regulations to write while we go do this.'"

A Tight Timeframe

Both Polston and Knickrehm agreed that the 2-year deadline to review all of the regulations may not be feasible. "I have a suite of regulations that control the Medicare and Medicaid programs; in hard copy it's five or six volumes of regulations, and that's just Medicare and Medicaid," said Polston.

"HHS has many more regulations than that, including FDA. They're really putting themselves on a tight schedule.... That's a very significant amount of work to do in a 2-year time period. It's ironic that a rule that has, probably as its purpose, to reduce a federal bureaucracy is probably creating an additional bureaucracy," he said.

Knickrehm said that 2 years "struck me as a particularly short time period" for the review. "Agencies are already investing quite a few resources in annual rulemaking, particularly at CMS," he said.

In a press release on the rule, HHS said that the rule will not impose undue or impractical burdens on agencies within HHS. "Agencies such as CMS already update significant amounts of regulations each year, including through annual payment rules," the press release states. "The department estimates investing approximately $10-26 million in this effort over 10 years. HHS' annual budget is more than $1 trillion."

In the proposed rule itself, the agency noted, "The department has roughly 18,000 regulations, the vast majority of which it believes would need to be assessed. Roughly 12,400 of these regulations are over 10 years old. The vast majority of these would need to be assessed within 2 years if this proposed rule were finalized. But because the department estimates that roughly five regulations on average are part of the same rulemaking, the number of assessments to perform in the first 2 years is estimated to be roughly 2,480."

The experts differed slightly on what would happen to the rule should former Vice President Biden be elected president. "Democrats have trouble with some regulations as well," said Wilensky. "If [the regulations] were written during a Republican period, they would be only too happy to revisit them and make them tougher."

Polston had a different take. "I think if there is a change in administration, this is one of those things they will pause immediately and want to take a strong look at it" and see whether they would want to move forward with it or withdraw it. "That's not uncommon in a change of administration," he said.

https://www.medpagetoday.com/publichealthpolicy/healthpolicy/89514

COVID-Related Strokes Especially Severe, Result in Worse Outcomes

Ischemic strokes in COVID-19 patients tended to be more severe than those in other individuals, according to a case-control study from the U.K.

Among 86 stroke patients with COVID-19, stroke characteristics and outcomes differed from uninfected stroke patients treated during the same period. The COVID-19-associated strokes:

  • Were more likely to involve multiple large vessel occlusions (17.9% vs 8.1%, P<0.03)
  • Were more severe (median NIH Stroke Scale score 8 vs 5, P<0.002)
  • Were associated with higher D-dimer levels (3.4 vs 3.0 ng/ml on the log10 scale, P<0.01)
  • Resulted in more severe disability on discharge (median modified Rankin Scale score 4 vs 3, P<0.0001)
  • Resulted in more deaths during index admission (19.8% vs 9.6%, P<0.0001)

"Our study provides the most compelling evidence yet that COVID-19-associated ischaemic strokes are more severe and more likely to result in severe disability or death, although the outlook is not quite as bleak as previous studies have suggested," according to a group led by Richard Perry, BM, BCh, PhD, of UCL Queen Square Institute of Neurology and the National Hospital for Neurology & Neurosurgery, London. A full manuscript was published in the Journal of Neurology, Neurosurgery & Psychiatry.

A median of 6 days elapsed from onset of COVID-19 symptoms to the onset of ischemic stroke among patients admitted to 13 centers in England and Scotland from March 9 to July 5 this year.

"The data are consistent with prior reports focused on stroke associated with COVID-19 and reinforces those findings," commented Larry B. Goldstein, MD, of University of Kentucky in Lexington.

"Large vessel strokes affect larger areas of the brain and are generally more severe, again consistent with the results of this study. This may in part be related to an increased tendency for persons with COVID-19 to form blood clots that can lead to stroke," he told MedPage Today.

Large vessel occlusion in COVID-19 may be a direct manifestation of a SARS-CoV-2-related hypercoagulable state -- as suggested by elevated D-dimers -- but levels of the biomarker varied substantially, suggesting much heterogeneity among patients, Perry and colleagues indicated.

"COVID-19 does not appear to influence stroke solely through a single mechanism; no single aetiological category of ischaemic stroke seems to have been more strongly associated with COVID-19 infection than the others," they wrote.

"We suggest that COVID-19 may provoke the onset of an ischaemic stroke through a variety of thrombotic and inflammatory mechanisms, promoting generation of thrombus in the heart or large vessels or via small vessel occlusion. Which of these mechanisms manifests in a given patient may be determined by that individual's conventional vascular risk factors such as atrial fibrillation, large vessel atheroma, hypertension or type 2 diabetes mellitus," study authors continued.

Perry's group relied on a combination of retrospective and prospective data collection for the study.

Early in the study period, SARS-CoV-2 testing was given to patients only if there was clinical suspicion of COVID-19. The proportion of asymptomatic patients tested rose progressively from 10.3% to 93.5% from the weeks of March 9 to May 11 before staying at a mean of 95.3% for the rest of the study, according to Perry and colleagues.

The 86 stroke patients had tested positive within 4 days of admission or stroke onset. They were split between 81 ischemic strokes and five intracerebral hemorrhages.

For comparison, Perry and colleagues examined records for 1,384 patients admitted during the same period who were either consistently SARS-CoV-2-negative or were never tested because they did not show symptoms or signs of COVID-19. This group counted 1,193 ischemic strokes and 191 intracerebral hemorrhages.

Overall, the cohort had a median age of 73 years, and roughly 53% were men.

Stroke patients with SARS-CoV-2 infection were not more likely to be younger or men, unlike previous reports. Rather, COVID-19 patients who had strokes were more likely to be Asian (18.8% vs 6.7% of non-COVID group, P<0.0001), Perry's team reported.

Recurrence of stroke during the patient's admission was similarly rare among COVID cases and controls (2.3% vs 1.0%).

Study authors noted that other large studies of COVID-19-associated stroke had used historical controls for comparison, biasing the results toward overestimating the influence of COVID-19 on stroke severity and any other parameters correlated with severity.

Nevertheless, their own study was subject to biases as well, given that some reports and tests were not available in all patients.

The case-control study also failed to include all consecutive cases during the study period.

"We anticipated that most centres would not be able to collect data on consecutive stroke admissions throughout the whole study period, so centres were asked to prioritise weeks during which patients with COVID-19 were admitted, and for any such week (Monday to Sunday) to include all strokes regardless of SARS-CoV-2 status," Perry's group noted.

For now, patients presenting with ischemic stroke and very elevated D-dimers with no other explanation should be tested for SARS-CoV-2 infection, the authors said. They added that people testing positive for COVID-19 may benefit from CT angiography because the finding of multiple large vessel occlusions may require a specific management strategy (i.e., mechanical thrombectomy or a different antithrombotic agent).

"On the other hand, in most patients with COVID-19-associated ischaemic stroke, very early anticoagulation is probably not warranted as a strategy to prevent inpatient stroke recurrence, as this outcome is too uncommon to justify the increased risk of secondary haemorrhage," according to the group.

"Finally, it is important to note that although less than 6% of the patients included in this report had COVID-19, because the disease affects persons of all ages, even young people need to know the symptoms of stroke and seek care immediately," Goldstein emphasized.

Disclosures

Perry and Goldstein disclosed no conflicts.

Study co-authors reported relationships with Bayer, Sanofi, Pfizer, Alnylam, and Portola.

https://www.medpagetoday.com/neurology/strokes/89509


What could aducanumab approval mean for future Alzheimer's R&D?

Experts and industry watchers fully expect the FDA to approve Biogen’s controversial Alzheimer’s disease drug aducanumab—but not because it’s a game changer. In the words of one analyst, aducanumab won’t get the agency’s nod because its data are strong, but rather “in spite of the quality” of those data.

But maybe it doesn’t need to be perfect, says Jim Kupiec, M.D., who previously led clinical research at Pfizer’s neuroscience unit in Cambridge, Massachusetts. Kupiec thinks aducanumab’s approval would pave the way for a group of newer, better drugs for Alzheimer’s, including some he’s working on at ProMIS Neurosciences as its chief medical officer.


“This has a modest benefit. If approved, it will be first in class, but it will never be the best in class,” Kupiec said of aducanumab.

“There is a whole generation of assets that are targeting amyloid in some fashion—antibodies or small molecules—that I’m very confident in saying will provide increased effectiveness and increased safety,” he added. “An approval here will, in fact, provide an environment in which all these additional next-generation anti-amyloid therapies are worked on in a very aggressive fashion with investment dollars providing support for additional phase 3 work.”


The new drug application for aducanumab will hinge on data from three studies, with an emphasis on a small phase 1b study dubbed PRIME or study 103, and a phase 3 study, EMERGE, also called study 302, that enrolled more than 1,600 patients. The third study, ENGAGE, or study 301, was of “essentially identical design” as EMERGE but was deemed a failure.

“Study 301 is a negative study and does not contribute to the evidence of effectiveness of aducanumab,” but it “may be understood well enough … to not represent evidence that the drug is ineffective,” FDA staff wrote in briefing documents released Wednesday.

Though the ENGAGE study is not part of the package to prove aducanumab's efficacy, the FDA will ask a panel of outside experts when it convenes Friday how the data affect their consideration of the EMERGE data and whether the EMERGE data can stand on their own as evidence that aducanumab works.

Biogen canned the phase 3 program in March of last year because it failed a futility analysis. Six months later, the company surprised everyone, Kupiec included, when it said it had made a mistake and that it would file aducanumab for approval.


What happened? Biogen looked at the phase 3 data that came in after an independent data monitoring board had started the futility analysis and decided the futility analysis was “incorrect.” The company concluded after a post hoc analysis that the EMERGE trial had actually succeeded, with patients on the highest dose of aducanumab logging a statistically significant improvement on a clinical dementia scale. But it also found that patients in the ENGAGE study did worse than patients taking placebo on that same measure, as well as on a test of cognitive function.

Although futility analyses are routine in drug development, this kind of flip-flop is rare.

“I’ve been in the business for 30 years and I’ve never seen anything like this. I’ve never seen a program in which a futility analysis was called and a program was stopped that a subsequent analysis showed to be positive, so this is highly unusual,” Kupiec said.


On Friday, the FDA will also ask the Peripheral and Central Nervous System Drugs Advisory Committee to consider the EMERGE data “independently and without regard for” the ENGAGE study, according to a set of draft questions (PDF) published Wednesday. But that ask raised red flags for some industry watchers.


In a prerecorded presentation to the panel, Tristan Massie, Ph.D., an FDA statistician, raised concerns about ignoring the ENGAGE study while considering the "essentially identical" EMERGE study.

“Study 301 fell dramatically short of study 302, and provides a stark contrast and challenge to the 302 results,” Massie said, according to a transcript of the presentation (PDF). That discrepancy could lead to questions about the reproducibility of experiments, Massie said, adding, “we do not have a single strong study in isolation. On the contrary, we actually have a second trial in which the purported effective dose was in the wrong direction compared to placebo, i.e., numerically worse than placebo.”

“Furthermore, if we select only the better study our estimate is very likely biased, and we already know not consistently repeatable in our experience. Thus excluding data from a large trial without sufficient justification is unscientific, statistically inappropriate and misleading,” Massie said.

Like Kupiec, Massie thinks an aducanumab approval would affect other Alzheimer’s treatments in development—but that it will cause more problems than it solves.


“For example, noninferiority would be questionable against these mixed divergent phase 3 results,” he said. “Outside of noninferiority, the need to demonstrate an add-on effect to this drug could create possibly powering and or practical issues.”

Finally, an approval could make it harder to recruit and retain patients for studies testing treatments that “potentially could have more consistent effects,” Massie said.

https://www.fiercebiotech.com/biotech/what-could-aducanumab-approval-mean-for-future-alzheimer-s-r-d

Drug wholesalers and J&J agree to tentative $26B deal to settle opioid lawsuits

Ironwood Pharma on the move after activist joins board